<DOC>
	<DOCNO>NCT01963481</DOCNO>
	<brief_summary>This phase II trial study well exemestane cyclophosphamide work treat patient estrogen receptor ( ER ) -positive , progesterone receptor ( PR ) -positive , human epidermal growth factor receptor ( HER ) 2-negative stage IV breast cancer .</brief_summary>
	<brief_title>Exemestane Cyclophosphamide Metastatic Breast Cancer</brief_title>
	<detailed_description>Estrogen cause growth breast cancer cell . Hormone therapy use exemestane may fight breast cancer block use estrogen tumor cell . Low dose cyclophosphamide may also stimulate white blood cell , include natural killer cell , instance decreasing suppressor ( regulatory ) T-cells . Giving exemestane cyclophosphamide may effective treatment estrogen receptor-positive , progesterone receptor-positive , HER2-negative stage IV breast cancer .</detailed_description>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Patients must histologically confirm breast cancer ER positive and/or PR positive , HER2/neu negative disease metastatic ( stage IV ) HER2/neu negative disease determine use commercially available/approved assay local institutional reference laboratory , accord American Society Clinical Oncology ( ASCO ) /College American Pathologists ( CAP ) guideline ( IHC 01+ 2+ HER2/17 ratio FISH &lt; = 1.8 ) . ER/PR expression perform standard immunohistochemical assay classify ER and/or PRpositive accord ASCO/CAP guideline ( 1100 % expression ) Histologic and/or cytologic confirmation metastatic disease encourage whenever feasible , furthermore , feasible , biopsy confirm metastatic tumor ER and/or PR positive HER2/neu negative . For patient histologic biopsy confirmation and/or assessment ER/PR/HER2 metastatic disease feasible , required primary tumor ER and/or PRpositive HER2/neu negative . Measurable disease ( RECIST 1.1 ) nonmeasurable ( assessable ) disease Patients must progressive disease least one line endocrine therapy metastatic disease recurrent disease within 12 month receive adjuvant endocrine therapy . Prior treatment accept include nonsteroidal aromatase inhibitor , tamoxifen , fulvestrant combination . Patients take bisphosphonates bone disease permit enter trial , bone lesion consider assessable response , although assessable progression . Female male subject age &gt; = 18 year . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Patients must normal organ marrow function define : absolute neutrophil count &gt; = 1,200/mcL platelet &gt; = 100,000/mcL hemoglobin &gt; = 9g/dl total bilirubin &lt; = 2 X upper limit normal ( ULN ) [ unless due Gilbert 's disease ] AST ( SGOT ) &lt; = 2.5 X ULN ALT ( SGPT ) &lt; = 2.5 X ULN creatinine &lt; = 1.5 X ULN Patients must able swallow tolerate oral medication . Postmenopausal status , define 60 year old , 45 year old amenorrhea x 12 month follicle stimulate hormone level within postmenopausal range , OR undergone bilateral oophorectomy . Ability understand willingness sign write informed consent document . Patients may receive investigational agent . Prior treatment breast cancer steroidal aromatase inhibitor ; exception patient start combination exemestane everolimus le 4 week prior study entry discontinue everolimus due poor tolerability . Presence life threaten metastatic visceral disease ( defined extensive hepatic involvement symptomatic pulmonary lymphangitic spread ) uncontrolled brain metastasis . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hormonal therapy</keyword>
	<keyword>immunotherapy</keyword>
</DOC>